Table 1.
Comparison of Anti-CD20s.
| Agent | Description | ADCC | CDC | Apoptosis | Binding |
|---|---|---|---|---|---|
| Ofatumumab (HuMax-CD20) | • Human IgG1 kappa backbone • Unique binding site • Phase I/II for NHL and CLL • Kills rituximab-resistant cell lines • 50% B-CLL killing vs. 5% Rituximab (in vitro) |
⬌ | ⬆ | ⬌ | ⬆ |
| Veltuzumab (hA20) | • Humanized • Re-shaped Rituximab binding region with epratuzumab backbone • Phase I/II for NHL • Similar binding affinity, apoptosis and in vitro data as rituximab |
⬌ | ⬌ | ⬌ | ⬌ |
| PRO131921 (rhuMAb v114) | • Humanized • Enhanced binding to FcyRIIIA • B-cell depletion superior to rituximab in murine models |
⬆ | ⬆ | ⬌ | ⬆ |
| AME-133 | • Humanized • Optimized via proprietary AME process (improved FcyRIII binding and ADCC) • 10-fold higher cell killing than rituximab |
⬆ | ⬌ | ⬌ | ⬆ |
| GA101 | • Humanized | ⬆ | ⬇ | ⬆ | ⬌ |